Entrada Therapeutics, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for TRDA, updated each market day.
TRDA AI Sentiment
AI sees no strong directional signal for Entrada Therapeutics, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Entrada Therapeutics, Inc. Common Stock
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Sector
Exchange
Market Cap
$537,894,597
Cap Tier
Employees
152
Headquarters
BOSTON, MA
Listed Since
Oct. 29, 2021
Website
TRDA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
TRDA Volatility
Entrada Therapeutics, Inc. Common Stock has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
